Ly93 |
Catalog No.GC64957
One-Click Copy Product Info
|
Ly93 es un inhibidor de la esfingomielina sintasa 2 (SMS2) selectivo y activo por vÍa oral, con una IC50 de 91 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1883528-69-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ly93 is a selective sphingomyelin synthase 2 (SMS2) inhibitor with an IC50 of 91nM[1]. By inhibiting SMS2, Ly93 reduces sphingomyelin levels, thereby exerting anti-inflammatory and anti-atherosclerotic effects. Ly93 can be used in research related to atherosclerosis, dry eye disease, and epilepsy[2-3].
In vitro, Jurkat, Hut-102, and other T-cell malignancy cell lines were pretreated with Ly93 (10µM) for 1 hour, followed by treatment with compound V8 (4–6µM) for 6 hours. Ly93 attenuated V8-induced lysosomal membrane damage (reduction in Galectin-3-positive puncta) and decreased intracellular sphingomyelin levels[4]. NRK (normal rat kidney) cells were pretreated with Ly93 (35µM) for 30 minutes, followed by exposure to TcdB3 (0.2pM) for 4 hours. Ly93 blocked TcdB3-induced migrasome formation[5].
In vivo, high-fat diet-induced insulin-resistant C57BL/6 mice were treated with Ly93 (20-40mg/kg) via intragastric administration once daily for 12 weeks. Ly93 significantly improved insulin sensitivity[6]. In C57BL/6J mice, administration of Ly93 (100mg/kg) via gavage once daily for 7 days significantly reduced plasma sphingomyelin levels. Furthermore, apolipoprotein E knockout (apoE KO) mice on a Western diet were treated with Ly93 (12.5-40mg/kg) via gavage once daily for 7 weeks. Ly93 dose-dependently attenuated atherosclerotic lesions in both the aortic root and the entire aorta and reduced macrophage content within the lesions[7].
References:
[1] Hua F, Wang HR, Bai YF, et al. Substance P promotes epidural fibrosis via induction of type 2 macrophages. Neural Regen Res. 2023 Oct;18(10):2252-2259.
[2] Wan J, Hu Z, Zhu H, et al. The essential role of sphingolipids in TRPC5 ion channel localization and functionality within lipid rafts. Pharmacol Res. 2025 Mar;213:107648. doi: 10.1016/j.phrs.2025.107648. Epub 2025 Feb 7.
[3] Chen Q, Wei Y, Wang L, et al. Ly93 Inhibits Sphingomyelin Synthesis and Attenuates Inflammation and Injury in Dry Eye Conjunctival Organoids. Invest Ophthalmol Vis Sci. 2026 Feb 2;67(2):58.
[4] Qing Y, Guo Y, Zhao Q, et al. Targeting lysosomal HSP70 induces acid sphingomyelinase-mediated disturbance of lipid metabolism and leads to cell death in T cell malignancies. Clin Transl Med. 2023 Mar;13(3):e1229.
[5] Li D, Yang Q, Luo J, et al. Bacterial toxins induce non-canonical migracytosis to aggravate acute inflammation. Cell Discov. 2024 Nov 5;10(1):112.
[6] Huang Y, Huang T, Zhen X, et al. A selective sphingomyelin synthase 2 inhibitor ameliorates diet induced insulin resistance via the IRS-1/Akt/GSK-3β signaling pathway. Pharmazie. 2019 Sep 1;74(9):553-558.
[7] Li Y, Huang T, Lou B, et al. Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor. Eur J Med Chem. 2019 Feb 1;163:864-882.
| Cell experiment [1]: | |
|
Cell lines |
NRK cells (normal rat kidney epithelial cell line) |
|
Preparation Method |
NRK cells stably overexpressing Tspan4-mCherry were cultured on glass-bottom plates precoated with fibronectin for 10-12 hours. The cells were then pretreated with Ly93 (35µM) for 30 minutes, followed by exposure to TcdB3 (0.2pM) for 4 hours. |
|
Reaction Conditions |
35µM; pretreatment for 30min. |
|
Applications |
Ly93 blocked TcdB3-induced migrasome formation (non-canonical migracytosis) in NRK cells. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6 mice |
|
Preparation Method |
Male C57BL/6 mice were fed a high-fat diet (HFD) to induce insulin resistance. During the last 12 weeks of the 16-week HFD feeding period, the mice were treated daily with Ly93 (20mg/kg and 40mg/kg) via intragastric administration (i.g.). A normal diet (ND) group served as the control. |
|
Dosage form |
20mg/kg and 40mg/kg; i.p.; Once daily for 12 weeks. |
|
Applications |
Ly93 administration significantly improved high-fat diet-induced insulin resistance. Ly93 reduced fasting blood insulin (Fins) levels and the homeostasis model assessment of insulin resistance (HOMA-IR) index, and enhanced insulin tolerance. Ly93 also increased glycogen content in the liver and skeletal muscle, and upregulated the phosphorylation of key insulin signaling proteins (IRS-1, Akt, and GSK-3β) in liver tissue. |
|
References: |
|
| Cas No. | 1883528-69-5 | SDF | |
| Formula | C21H20N2O2 | M.Wt | 332.4 |
| Solubility | DMSO : 250 mg/mL (752.11 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0084 mL | 15.0421 mL | 30.0842 mL |
| 5 mM | 601.7 μL | 3.0084 mL | 6.0168 mL |
| 10 mM | 300.8 μL | 1.5042 mL | 3.0084 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)